Systemic adoptive immunotherapy of a highly immunogenic murine lymphoma growing in the brain.
Systemic adoptive immunotherapy with specifically immune lymphocytes was successfully performed in immunodepressed mice challenged intracerebrally with L5178Y/DTIC lymphoma cells, a tumor subline rendered highly immunogenic through in vivo exposure to 5-(3,3-dimethyl-1-triazenyl)-IH-imidazole-4-carboxamide (DTIC). The systemic immunotherapy relied on the infusion of the in vitro-generated primary cytotoxic T-lymphocytes (CTL), the anti-tumor activity of which was evaluated by measuring tumor-cell proliferation in the brain in terms of radiolabel uptake and by recording survival times of recipient leukemic mice. The protection afforded by CTL appeared to be specific and was largely conditioned by dose and time of CTL administration. The levels of protection correlated well with the in vitro killing of L5178Y/DTIC tumor cells.